Factor v G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T are not associated with coronary artery disease and type 2 diabetes mellitus in western Iran

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 4, 2009, Pages 252-256

  Rahimi, Zohreh ^a,b   Nomani, Hamid ^b   Mozafari, Hadi ^a   Vaisi Raygani, Asad ^b   Madani, Hamid ^b   Malek Khosravi, Shohreh ^b   Parsian, Abbas ^c  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Coronary artery disease; Diabetes; Factor v leiden; Iran; Methylentetrahydrofolate reductase; Prothrombin g2021 OA; Western

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROL GROUP; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DNA EXTRACTION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; IRAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SUBSTITUTION; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FACTOR V; FEMALE; HUMANS; IRAN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTHROMBIN; THROMBOPHILIA;

EID: 67649531257     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283255487     Document Type: Article

References (34)

1. Pathare A, Al Kindi S, Al Haddabi H, Donnison D, Bayoumi R, Muralitharan S. Hereditary thrombophilia in ethnic Omani patients. Am J Hemato. 2006; 81:101-106.
2. Boekholdt SM, Bijslerveld NR, Moons AHM, Levi M, BullerHR, Peters RJG. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction. Circulatio. 2001; 104:3063-3068.
3. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210G to A) increases the risk of myocardial infarction in young women. Stoo. 1997; 90:1747-1750.
4. Ridker PM, Hennekens CH, Lindpaintner K, Stampeer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Me. 1995; 332:912-917.
5. Ridker PM, Hennekens CH, Miletich JP. G2021 OA mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulatio. 1999; 99:999-1004.
6. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, ef al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Bloo. 1997; 89:2817-2821.
7. Inbal A, Freimark D, Modan B, Chetrit A, Matetzky S, Rosenberg N, et al. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Bloo. 1999; 93:2186-2190.
8. Almawi WY, Ameen G, Tamin H, Finan RR, Irani-Hakime N. Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographically documented coronary artery disease. J Thromb Thrombolysi. 2004; 17:199-205.
9. Dacosta A, Tardy-Poncet B, Isaaz K, Cerisier A, Mismetti P, Simitsidis S, et al. Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries. Hear. 1998; 80:338-340.
10. Wu AH, Tsongalis GJ. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardio. 2001; 87:1361-1366.
11. Krekora K, Delucia D, Capani F, Donati MD, lacoviello L Association of coagulation factor V-Arg506Gln mutation with noninsulin-dependent diabetes mellitus. Lance. 1996; 348:1666-1667.
12. Hart LM, Stolk RP, Dekker JM, Nijpels G, Grobbee DE, Heine PJ, Maassen JA. Prevalence of variants in candidate genes for type 2 diabetes mellitus in the Netherlands: the Rotterdam study and the Hoorn study. J Clin Endocrinol Meta. 1999; 84:1002-1006. *
13. Wakim-Ghorayeb SF, Keleshian SH, Timson G, Finan RR, Najm P, Irani-Hakime N, Almawi WY. Factor V G1691A (Leiden) and prothrombin G2021 OA single-nucleotide polymorphisms in type 2 diabetes mellitus. Am J Hemato. 2005; 80:84-86.
14. WHO Study Group Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. World Health Organization: Geneva; 1999.
15. Old JM, Higgs DR. Gene analysis. In: Weatherall DJ, editor. Methods in hematology. The thalassemias. (Vol. 6). London: Churchill Livingstone; 1983. pp. 74-101.
16. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ.de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Natur. 1994; 369:64-67.
17. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Bloo. 1996; 88:3698-3703.
18. Frosst P, Blom HI, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Na. Genef 1995; 10:111 -113.
19. Segev A, Ellis MH, Segev F, Friedman Z, Reshef T, Sparkes JD, et al. High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors. Int J Cardio. 2005; 98: 421 -424.
20. Rahimi Z, Vaisi-Raygani A, Mozafari H, Kharrazi H, Rezaei M, Nagel RL. Prevalence of factor V Leiden (G1691A) and prothrombin (G20210A) among Kurdish population from Western Iran. J Thromb Thrombolysi. 2008; 25:280-283.
21. Gowda MS, Zucker ML, Vacek JL, Carriger WL, Van Laeys DL, Rachel JM, Strope BD. Incidence of factor V Leiden in patients with acute myocardial infarction. J Thromb Thrombolysi. 2000; 9:43-45.
22. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, et al. Myocardial infarction, Arg 506 to Gin factor V mutation, and activated protein C resistance, iancef 1995; 345:321.
23. Gurlertop HY, Gundogdu F, Pirim I, Islamoglu Y, Egercia N, Sevimli S, et al. Association between factor V Leiden mutation and coronary artery disease in the northeast region of Turkey. Stood Coagul Fibrinolysi. 2007; 18:719-722.
24. Abu-Amero KK, Wyngaard CA, Kambouris M, Dzimiri N. Prevalence of the 2021OG→A prothrombin variant and its association with coronary artery disease in a Middle Eastern Arab population. Arch Pathol Lab Me. 2002; 126:1087-1090.
25. Russo C, Girelli D, Olivieri O, Guarini P, Manzato F, Pizzolo F, et al. G20210A prothrombin gene polymorphism and prothrombin activity in subjects with or without angiographically documented coronary artery disease. Circulatio. 2001; 103:2436-2440.
26. Hobikoglu GF, Akyuz U, Akyuz F, Ozer O, Giïney D, Narin A, Unaltuna N, et al. Factor V Leiden is a risk factor for myocardial infarction in young Turkish men. Acta Cardio. 2004; 59:594-597.
27. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses. Bloo. 2002; 100:3-10.
28. Kawashiri M, Kajinami K, Nohara A, Yagi K, Inazu A, Koizumi J, Mabuchi H. Effect of common methylenetetrahydrofolate reductase gene mutation on coronary artery disease in familial hypercholesterolemia. Am J Cardio. 2000; 86:840-845.
29. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R, et al. Homocysteine and risk of premature coronary heart disease: evidence for a common gene mutation. Circulatio. 1996; 94:2154-2158.
30. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C→T polymorphism and risk of coronary heart disease: a metaanalysis. JAM. 2002; 288:2023-2031.
31. Kalina A, Czeizel AE. The methylenetetrahydrofolate reductase gene polymorphism (C677T) is associated with increased cardiovascular mortality in Hungary. Int J Cardio. 2004; 97:333-334.
32. Mukherjee M, Joshi S, Bagadi S, Dalvi M, Rao A, Shetty KR. A low prevalence of the C677T mutation in the methylenetetrahydrofolate reductase gene in Asian Indians. Clin Gene. 2002; 61:155-159.
33. Jee SH, Beaty TH, Suh I, Yoon Y, Appel U. The methylenetetrahydrofolate reductase gene is associated with increased cardiovascular risk in Japan, but not in other populations. Atherosclerosi. 2000; 153:161 -168.
34. Demirer AN, Alikasifoglu M, Tuncbilek E, Karakus S, Erbas T. Factor V Leiden mutation and type 1 diabetes mellitus. Stood Coagul Fibrinolysi. 2008; 19:70-74.